SCHEMBL2619296

SCHEMBL2619296

CCOc1cc2c(c(OC)c1OC)-c1ccc(S)c(=O)cc1[C@@H](N)CC2

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GNG2 P59768 1/20 0.67
GNB1 P62873 1/20 0.67
CYP3A4 P08684 2/20 0.64
HIF1A Q16665 2/20 0.64
KDM4E B2RXH2 1/20 0.64
USP2 O75604 1/20 0.64
TDP1 Q9NUW8 1/20 0.64
TUBB4A P04350 10/20 0.62
TUBB P07437 10/20 0.62
TUBA3C P0DPH7 10/20 0.62
TUBA1B P68363 10/20 0.62
TUBA4A P68366 10/20 0.62
TUBB4B P68371 10/20 0.62
TUBB3 Q13509 10/20 0.62
TUBB2A Q13885 10/20 0.62
TUBB8 Q3ZCM7 10/20 0.62
TUBA3E Q6PEY2 10/20 0.62
TUBA1A Q71U36 10/20 0.62
TUBA1C Q9BQE3 10/20 0.62
TUBB6 Q9BUF5 10/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18866851 0.89 GNG2 (0.69) GNG2GNB1CYP3A4HIF1AKDM4E
SCHEMBL21104787 0.88 GNG2 (0.84) GNG2GNB1CYP3A4HIF1AKDM4E
SCHEMBL12091269 0.86 TUBB4A (0.83) GNG2GNB1CYP3A4HIF1AKDM4E
SCHEMBL1401770 0.86 TUBB4A (0.83) GNG2GNB1CYP3A4HIF1AKDM4E
SCHEMBL12091230 0.84 GNG2 (0.84) GNG2GNB1CYP3A4HIF1AKDM4E
Deacetylcolchicine SCHEMBL13259801 0.81 GNG2 (1.00) GNG2GNB1CYP3A4HIF1AKDM4E
Deacetylcolchicine SCHEMBL13622201 0.81 GNG2 (1.00) GNG2GNB1CYP3A4HIF1AKDM4E
Deacetylcolchicine SCHEMBL29915209 0.81 GNG2 (1.00) GNG2GNB1CYP3A4HIF1AKDM4E
Deacetylcolchicine SCHEMBL12091279 0.81 GNG2 (1.00) GNG2GNB1CYP3A4HIF1AKDM4E
SCHEMBL16120997 0.79 GNG2 (0.83) GNG2GNB1CYP3A4HIF1AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120101296-A1 METHOD FOR PREPARING TRICYCLIC DERIVATIVES JE IL PHARMACEUTICAL CO., LTD. (KR) 2012-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120101296-A1 METHOD FOR PREPARING TRICYCLIC DERIVATIVES NISCH, CA3, CYP51A1 GNG2 2901/4885GNB1 3350/4885CYP3A4 85/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.